Home » Topics » HIV/AIDS, BioWorld Science

HIV/AIDS, BioWorld Science
RSS

Chimerix and ContraVir establish strategic collaboration for CMX-157

Dec. 23, 2014

Cellectis and bluebird bio report development of HIV treatment

Dec. 19, 2014

ViiV Healthcare applies for Japanese approval of dolutegravir/abacavir/lamivudine

Dec. 16, 2014

Complera combination tablet for HIV-1 launched in Japan

Dec. 15, 2014

FDA gives tentative approval to abacavir/lamivudine pediatric formulations

Dec. 5, 2014

Abivax completes first-in-human study of ABX-464

Dec. 3, 2014

Merck & Co. divulges HIV integrase inhibitors

Nov. 27, 2014

R-Pharm enters into an agreement with Bristol-Myers Squibb for Reyataz

Nov. 21, 2014

Theravectys updates on phase I/II trial of lentiviral vector HIV vaccine

Nov. 20, 2014

Vacc-4x and lenalidomide increase CD4 count in phase I/II trial in patients with HIV infection

Nov. 18, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 6, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...